Users Online: 627
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 

    Article Cited by others

DRUG REVIEW

Crizotinib: A comprehensive review

Sahu Arvind, Prabhash Kumar, Noronha Vanita, Joshi Amit, Desai Saral

Year : 2013| Volume: 2| Issue : 2 | Page no: 91-97

   This article has been cited by
 
1 Synthesis, molecular structure, and metabolic stability of new series of Næ -(2-alkylthio-4-chloro-5-methylbenzenesulfonyl)-1-(5-phenyl-1 H -pyrazol-1-yl)amidine as potential anti-cancer agents
Aneta Pogorzelska,Jaroslaw Slawinski,Anna Kawiak,Beata Zolnowska,Jaroslaw Chojnacki,Grzegorz Stasilojc,Szymon Ulenberg,Krzysztof Szafranski,Tomasz Baczek
European Journal of Medicinal Chemistry. 2018; 155: 670
[Pubmed]  [Google Scholar] [DOI]
2 Effective Treatment of Choroidal Metastasis With ALK Inhibitor Chemotherapy That Crosses the Blood–Brain Barrier
Michael Possin,Michael Altaweel
Journal of VitreoRetinal Diseases. 2018; 2(2): 115
[Pubmed]  [Google Scholar] [DOI]
3 The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 ‘CREATE’
Patrick Schöffski,Agnieszka Wozniak,Michael G. Leahy,Steinar Aamdal,Piotr Rutkowski,Sebastian Bauer,Stephan Richter,Viktor Grünwald,Maria Debiec-Rychter,Raf Sciot,Birgit Geoerger,Sandrine Marréaud,Sandra Collette,Axelle Nzokirantevye,Sandra J. Strauss
European Journal of Cancer. 2018; 94: 156
[Pubmed]  [Google Scholar] [DOI]
4 Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer
Takeshi Hirota,Shota Muraki,Ichiro Ieiri
Clinical Pharmacokinetics. 2018;
[Pubmed]  [Google Scholar] [DOI]
5 Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial
Patrick Schöffski,Jozef Sufliarsky,Hans Gelderblom,Jean-Yves Blay,Sandra J Strauss,Silvia Stacchiotti,Piotr Rutkowski,Lars H Lindner,Michael G Leahy,Antoine Italiano,Nicolas Isambert,Maria Debiec-Rychter,Raf Sciot,Thomas Van Cann,Sandrine Marréaud,Axelle Nzokirantevye,Sandra Collette,Agnieszka Wozniak
The Lancet Respiratory Medicine. 2018;
[Pubmed]  [Google Scholar] [DOI]
6 Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment
Jianya Zhou,Jing Zheng,Xiaochen Zhang,Jing Zhao,Yanping Zhu,Qian Shen,Yuehong Wang,Ke Sun,Zeying Zhang,Zhijie Pan,Yihong Shen,Jianying Zhou
BMC Cancer. 2018; 18(1)
[Pubmed]  [Google Scholar] [DOI]
7 Axl inhibitors as novel cancer therapeutic agents
Yingying Shen,Xiguang Chen,Jun He,Duanfang Liao,Xuyu Zu
Life Sciences. 2018;
[Pubmed]  [Google Scholar] [DOI]
8 A major component of vitamin E, a-tocopherol inhibits the anti-tumor activity of crizotinib against cells transformed by EML4-ALK
Yuki Uchihara,Takayuki Kidokoro,Kenji Tago,Tadahiko Mashino,Hiroomi Tamura,Megumi Funakoshi-Tago
European Journal of Pharmacology. 2018; 825: 1
[Pubmed]  [Google Scholar] [DOI]
9 Alpha-tocopherol attenuates the anti-tumor activity of crizotinib against cells transformed by NPM-ALK
Yuki Uchihara,Fumihito Ueda,Kenji Tago,Yosuke Nakazawa,Tomoyuki Ohe,Tadahiko Mashino,Shigenobu Yokota,Tadashi Kasahara,Hiroomi Tamura,Megumi Funakoshi-Tago,Jung Weon Lee
PLOS ONE. 2017; 12(8): e0183003
[Pubmed]  [Google Scholar] [DOI]
10 Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’
P Schöffski,A Wozniak,B Kasper,S Aamdal,M G Leahy,P Rutkowski,S Bauer,H Gelderblom,A Italiano,L H Lindner,I Hennig,S Strauss,B Zakotnik,A Anthoney,L Albiges,J -Y Blay,P Reichardt,J Sufliarsky,W T A van der Graaf,M Debiec-Rychter,R Sciot,T Van Cann,S Marréaud,T Raveloarivahy,S Collette,S Stacchiotti
Annals of Oncology. 2017;
[Pubmed]  [Google Scholar] [DOI]
11 Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer
Avital Lev,Safoora Deihimi,Elena Shagisultanova,Joanne Xiu,Amriti R. Lulla,David T. Dicker,Wafik S. El-Deiry
Cancer Biology & Therapy. 2017; : 1
[Pubmed]  [Google Scholar] [DOI]
12 Development of crizotinib, a rationally designed tyrosine kinase inhibitor for non-small cell lung cancer
Candice C. Poon,John J. Kelly
International Journal of Cancer. 2017;
[Pubmed]  [Google Scholar] [DOI]
13 Use of precision methods to accelerate drug development in oncology
Geraldine O’Sullivan Coyne,S. Percy Ivy,Barbara A. Conley
Expert Review of Precision Medicine and Drug Development. 2017; 2(2): 109
[Pubmed]  [Google Scholar] [DOI]
14 Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’
P. Schöffski,A. Wozniak,S. Stacchiotti,P. Rutkowski,J.-Y. Blay,L. H. Lindner,S. J. Strauss,A. Anthoney,F. Duffaud,S. Richter,V. Grünwald,M. G. Leahy,P. Reichardt,J. Sufliarsky,W. T. van der Graaf,R. Sciot,M. Debiec-Rychter,T. van Cann,S. Marréaud,M. Lia,T. Raveloarivahy,L. Collette,S. Bauer
Annals of Oncology. 2017;
[Pubmed]  [Google Scholar] [DOI]
15 HPLC method development and validation for the estimation of axitinibe in rabbit plasma
Achanta Suneetha,Sharmila Donepudi
Brazilian Journal of Pharmaceutical Sciences. 2017; 53(3)
[Pubmed]  [Google Scholar] [DOI]
16 F1174V Mutation Alters the ALK Active Conformation in Response to Crizotinib in NSCLC: Insight from Molecular Simulations
Fariba Dehghanian,Maryam Kay,Sadeq Vallian
Journal of Molecular Graphics and Modelling. 2017;
[Pubmed]  [Google Scholar] [DOI]
17 Synergism between ivermectin and the tyrosine kinase/P-glycoprotein inhibitor crizotinib against Haemonchus contortus larvae in vitro
Ali Raza,Steven R. Kopp,Andrew C. Kotze
Veterinary Parasitology. 2016; 227: 64
[Pubmed]  [Google Scholar] [DOI]
18 Crizotinib: from discovery to accelerated development to front-line treatment
F. Blackhall,F. Cappuzzo
Annals of Oncology. 2016; 27(suppl_3): iii35
[Pubmed]  [Google Scholar] [DOI]
19 ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer
Haiyan Sun,Christopher G. England,Reinier Hernandez,Stephen A. Graves,Rebecca L. Majewski,Anyanee Kamkaew,Dawei Jiang,Todd E. Barnhart,Yunan Yang,Weibo Cai
European Journal of Nuclear Medicine and Molecular Imaging. 2016;
[Pubmed]  [Google Scholar] [DOI]
20 Pharmacogenomics and targeted therapy of Cancer: Focusing on Non-small cell lung Cancer
Seyyed Mortaza Haghgoo,Abdolamir Allameh,Esmaeil Mortaz,Johan Garssen,Gert Folkerts,Peter J. Barnes,Ian M. Adcock
European Journal of Pharmacology. 2015;
[Pubmed]  [Google Scholar] [DOI]
21 A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients
Alana Dikopf,Kevin Wood,Ravi Salgia
Expert Opinion on Drug Safety. 2015; 14(3): 485
[Pubmed]  [Google Scholar] [DOI]
22 RESPONSE OF UVEAL METASTASES TO ALK INHIBITORS IN ALK-POSITIVE NON–SMALL-CELL LUNG CANCER
Amro Abdellatief,Julian R. Molina,Jose S. Pulido
Retinal Cases & Brief Reports. 2015; : 1
[Pubmed]  [Google Scholar] [DOI]
23 Precision medicine in oncology drug development: a pharma perspective
Simon J. Hollingsworth
Drug Discovery Today. 2015; 20(12): 1455
[Pubmed]  [Google Scholar] [DOI]
24 Analysis of ALK gene in 133 patients with breast cancer revealed polysomy of chromosome 2 and no ALK amplification
Matthew G. Hanna,Vesna Najfeld,Hanna Y. Irie,Joseph Tripodi,Anupma Nayak
SpringerPlus. 2015; 4(1)
[Pubmed]  [Google Scholar] [DOI]
25 AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective
Samuel H. Myers,Valerie G. Brunton,Asier Unciti-Broceta
Journal of Medicinal Chemistry. 2015;
[Pubmed]  [Google Scholar] [DOI]
26 Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth
Coralie Hoareau-Aveilla,Thibaud Valentin,Camille Daugrois,Cathy Quelen,Géraldine Mitou,Samuel Quentin,Jinsong Jia,Salvatore Spicuglia,Pierre Ferrier,Monica Ceccon,Sylvie Giuriato,Carlo Gambacorti-Passerini,Pierre Brousset,Laurence Lamant,Fabienne Meggetto
Journal of Clinical Investigation. 2015; 125(9): 3505
[Pubmed]  [Google Scholar] [DOI]
27 Molecular biomarkers in clinical development: what could we learn from the clinical trial registry?
Avisek Deyati,Rama Devi Sanam,Sreenivasa Rao Guggilla,Vijaya Rao Pidugu,Natalia Novac
Personalized Medicine. 2014; 11(4): 381
[Pubmed]  [Google Scholar] [DOI]
28 Anaplastic lymphoma kinase (ALK) inhibitors: a review of design and discovery
Wen-Chieh Wang,Hui-Yi Shiao,Chieh-Chien Lee,Ka-Shu Fung,Hsing-Pang Hsieh
MedChemComm. 2014; 5(9): 1266
[Pubmed]  [Google Scholar] [DOI]

 

Read this article